Almont, 5 mg 98 pcs.

Bronchospasm, Runny nose (rhinitis), Bronchial asthma

Prevention and long-term treatment of bronchial asthma in children, including:

• preventing daytime and nighttime symptoms of the disease (for children 2 years and older);
• Treatment of bronchial asthma in patients with hypersensitivity to acetylsalicylic acid (for children 6 years and older);
• preventing exercise-induced bronchospasm (for children 2 years and older).

Promotion of symptoms of seasonal and year-round allergic rhinitis in children from 2 years of age.

Indications

Prevention and long-term treatment of bronchial asthma in children, including:

prevention of daytime and nighttime symptoms of the disease (for children aged 2 years and older);
treatment of bronchial asthma in patients with hypersensitivity to acetylsalicylic acid (for children aged 6 years and older);
prevention of bronchospasm caused by physical activity (for children aged 2 years and older).

Relief of symptoms of seasonal and year-round allergic rhinitis in children from 2 years of age.

Pharmacological effect

Pharmacotherapeutic group:

Special instructions

The drug ALMONT is not recommended for the treatment of acute attacks of bronchial asthma. Patients with bronchial asthma are advised to always carry emergency medications with them. When an acute attack occurs, short-acting inhaled beta2-agonists should be used. Patients should consult their physician as soon as possible if they require more inhaled short-acting beta2-agonists than usual.

Active ingredient

Montelukast

Composition

Active substance:

montelukast 5.00 mg (as montelukast sodium 5.20 mg);

excipients:

mannitol 201.20 mg,

microcrystalline cellulose 66.00 mg,

hyprolose 9.00 mg,

croscarmellose sodium 9.00 mg,

dye Pigment Blend PB-24880 (lactose monohydrate 4.50 mg, red iron oxide dye 0.50 mg) 5.00 mg,

magnesium stearate 3.00 mg,

aspartame 1.50 mg,

cherry flavor (Silarom Cherry Flavor 1219813182) 0.10 mg.

Pregnancy

The use of Almont during pregnancy is possible if the expected benefit to the mother outweighs the potential risk to the fetus.

Contraindications

Hypersensitivity to the active or any excipient of the drug;
children up to 2 years of age (for a dosage of 4 mg) and up to 6 years of age (for a dosage of 5 mg);
patients with rare hereditary diseases: galactose intolerance, lactase deficiency or glucose-galactose malabsorption;
phenylketonuria (contains aspartame).

Side Effects

Infectious and parasitic diseases: upper respiratory tract infections.

Interaction

In patients simultaneously receiving phenobarbital, the area under the pharmacokinetic concentration-time curve of montelukast decreased by approximately 40%, but no dosage adjustment is required in such patients. Since montelukast is metabolized by CYP3A4, caution should be exercised, especially in children, if montelukast is co-administered with CYP3A4 inducers such as phenytoin, phenobarbital and rifampicin.

Overdose

Symptoms of drug overdose in patients with chronic bronchial asthma when used at a dose exceeding 200 mg per day for 22 weeks and at a dose of 900 mg per day for 1 week have not been identified.

There are reports of acute overdose of montelukast (when taking at least 1 g per day) in the post-marketing period and in clinical studies in adults and children. Clinical and laboratory data indicate that the safety profile of the drug is consistent in children, adults and elderly patients. The most common symptoms were thirst, drowsiness, vomiting, psychomotor agitation, headache and abdominal pain.

Treatment: symptomatic therapy.

There are no data on the possibility of removing montelukast by peritoneal dialysis or hemodialysis.

Shelf life

3 years.

Manufacturer

Iceland